| **Author, year** | **Group1** | **Group2** | **Outcome (definition)** | **AE collection / ITT** | **Results, Group 1** | **Results, Group 2** |
| --- | --- | --- | --- | --- | --- | --- |
| Colombel, 201045 | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 55 / 169 (32.5%) | Incidence 30 / 170 (17.6%) P: 0.001 |
| Colombel, 201045 | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | CDAI (Remission: CDAI < 150) @ 26 wks | NAYes | Incidence 81 / 169 (47.9%) | Incidence 54 / 170 (31.8%) P: 0.002 |
| Colombel, 201045 | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | CDAI (Remission: CDAI < 150) @ 50 wks | NAYes | Incidence 64 / 169 (38%) | Incidence 41 / 170 (24%) P: 0.006 |
| Colombel, 201045 | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | Endoscopic healing (Absence of ulcers) @ 26 wks | NANo | Incidence 28 / 93 (30%) | Incidence 18 / 109 (17%) P: 0.02 |
| Colombel, 201045 | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | HR QoL (IBDQ) @ 26 wks | NAYes | B: Mean, 126.7 (SD, 30)F-B: Mean, 39.9 (SD, 37)G1-G2: -8.5 | B: Mean, 122.1 (SD, 30)F-B: Mean, 31.4 (SD, 35)G1-G2: -8.5 P: 0.05 |
| Colombel, 201045 | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | HR QoL (IBDQ) @ 26 wks | NAYes | F-B: Mean, 27.7 (SD, 26)G1-G2: -7.6 | F-B: Mean, 20.1 (SD, 24)G1-G2: -7.6 P: 0.007 |
| Colombel, 201045 | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | HR QoL (IBDQ) @ 50 wks | NANo | F-B: Mean, 51.6 (SD, 33)G1-G2: -8.6 | F-B: Mean, 43 (SD, 33)G1-G2: -8.6 |
| Colombel, 201045 | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | Steroid free (steroid-free remission (CDAI < 150)) @ 26 wks | NAYes | Incidence 75 / 169 (44.4%) | Incidence 51 / 170 (30%) P: 0.006 |
| Colombel, 201045 | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | Steroid free (steroid-free remission (CDAI < 150)) @ 50 wks | NAYes | Incidence 59 / 169 (35%) | Incidence 41 / 170 (24%) P: 0.03 |
| Colombel, 201045 | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | Steroid free (steroid-free remission (CDAI < 150)) @ 6 wks | NAYes | Incidence 50 / 169 (29.6%) | Incidence 24 / 170 (14.1%) |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 62 / 169 (36.7%) | Incidence 30 / 170 (17.6%) P: <0.001 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | CDAI (Remission: CDAI < 150) @ 26 wks | NAYes | Incidence 102 / 169 (60.4%) | Incidence 54 / 170 (31.8%) P: <0.001 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | CDAI (Remission: CDAI < 150) @ 50 wks | NAYes | Incidence 80 / 169 (47%) | Incidence 41 / 170 (24%) P: <0.001 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | Endoscopic healing (Absence of ulcers) @ 26 wks | NANo | Incidence 47 / 107 (44%) | Incidence 18 / 109 (17%) |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | HR QoL (IBDQ) @ 26 wks | NAYes | F-B: Mean, 31.4 (SD, 30)G1-G2: -11.3 | F-B: Mean, 20.1 (SD, 24)G1-G2: -11.3 P: <0.001 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | HR QoL (IBDQ) @ 26 wks | NAYes | B: Mean, 125.3 (SD, 29)F-B: Mean, 45.2 (SD, 36)G1-G2: -13.8 | B: Mean, 122.1 (SD, 30)F-B: Mean, 31.4 (SD, 35)G1-G2: -13.8 P: <0.001 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | HR QoL (IBDQ) @ 50 wks | NANo | F-B: Mean, 56.4 (SD, 33)G1-G2: -13.4 | F-B: Mean, 43 (SD, 33)G1-G2: -13.4 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | Steroid free (steroid-free remission (CDAI < 150)) @ 50 wks | NAYes | Incidence 78 / 168 (46%) | Incidence 41 / 170 (24%) P: <0.001 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | Steroid free (steroid-free remission (CDAI < 150)) @ 6 wks | NAYes | Incidence 55 / 169 (32.5%) | Incidence 24 / 170 (14.1%) P: <0.001 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Azathioprine + placeboRoute: Oral + IVDose: 2.5 mg/kg daily + NA every 8 wks | Steroid free (steroid-free remission (CDAI < 150)) @ 26 wks | NAYes | Incidence 96 / 169 (56.8%) | Incidence 51 / 170 (30%) P: <0.001 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 62 / 169 (36.7%) | Incidence 55 / 169 (32.5%) P: 0.38 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | CDAI (Remission: CDAI < 150) @ 26 wks | NAYes | Incidence 102 / 169 (60.4%) | Incidence 81 / 169 (47.9%) P: 0.02 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | CDAI (Remission: CDAI < 150) @ 50 wks | NAYes | Incidence 80 / 169 (47%) | Incidence 64 / 169 (38%) P: 0.08 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Endoscopic healing (Absence of ulcers) @ 26 wks | NANo | Incidence 47 / 107 (44%) | Incidence 28 / 93 (30%) P: 0.06 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | HR QoL (IBDQ) @ 26 wks | NAYes | B: Mean, 125.3 (SD, 29)F-B: Mean, 45.2 (SD, 36)G1-G2: -5.3 | B: Mean, 126.7 (SD, 30)F-B: Mean, 39.9 (SD, 37)G1-G2: -5.3 P: 0.13 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | HR QoL (IBDQ) @ 26 wks | NAYes | F-B: Mean, 31.4 (SD, 30)G1-G2: -3.7 | F-B: Mean, 27.7 (SD, 26)G1-G2: -3.7 P: 0.31 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | HR QoL (IBDQ) @ 50 wks | NANo | F-B: Mean, 56.4 (SD, 33)G1-G2: -4.8 | F-B: Mean, 51.6 (SD, 33)G1-G2: -4.8 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Steroid free (steroid-free remission (CDAI < 150)) @ 26 wks | NAYes | Incidence 96 / 169 (56.8%) | Incidence 75 / 169 (44.4%) P: 0.02 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Steroid free (steroid-free remission (CDAI < 150)) @ 50 wks | NAYes | Incidence 78 / 168 (46%) | Incidence 59 / 169 (35%) P: 0.04 |
| Colombel, 201045 | Azathioprine + infliximabRoute: Oral + IVDose: 2.5 mg/kg daily + 5 mg/kg every 8 wks | Infliximab + placeboRoute: IV + OralDose: 5 mg/kg every 8 wks + NA daily | Steroid free (steroid-free remission (CDAI < 150)) @ 6 wks | NAYes | Incidence 55 / 169 (32.5%) | Incidence 50 / 169 (29.6%) P: 0.55 |
| Reinisch, 200851 | Azathioprine + prednisoneRoute: Oral + OralDose: 2.5 mg/kg daily + 1 mg/kg or ≥ 40 mg daily | Placebo + prednisoneRoute: Oral + OralDose: NA daily + 1mg/kg or ≥ 40mg daily | HR QoL (IBDQ) @ 4 wks | NANo | F-B: Median, 43G1-G2: -3 | F-B: Median, 40G1-G2: -3 |
| D'Haens, 200848 | Budesonide + (6)-methylprednisoloneRoute: Oral + OralDose: 9 mg daily + 32 mg daily | Infliximab + azathioprineRoute: IV + OralDose: 5 mg/kg + 2-2.5 mg/kg | CDAI (Remission: CDAI<150, absence of intestinal resection, absence of corticosteroid therapy) @ 104 wks | NAYes | Incidence 32 / 64 (50%) | Incidence 36 / 65 (55%) P: 0.431 |
| D'Haens, 200848 | Budesonide + (6)-methylprednisoloneRoute: Oral + OralDose: 9 mg daily + 32 mg daily | Infliximab + azathioprineRoute: IV + OralDose: 5 mg/kg + 2-2.5 mg/kg | CDAI (Remission: CDAI<150, absence of intestinal resection, absence of corticosteroid therapy) @ 26 wks | NAYes | Incidence 23 / 64 (36%)  | Incidence 39 / 65 (60%) P: 0.0062 |
| D'Haens, 200848 | Budesonide + (6)-methylprednisoloneRoute: Oral + OralDose: 9 mg daily + 32 mg daily | Infliximab + azathioprineRoute: IV + OralDose: 5 mg/kg + 2-2.5 mg/kg | CDAI (Remission: CDAI<150, absence of intestinal resection, absence of corticosteroid therapy) @ 52 wks | NAYes | Incidence 27 / 64 (42%)  | Incidence 40 / 65 (62%) P: 0.0278 |
| D'Haens, 200848 | Budesonide + (6)-methylprednisoloneRoute: Oral + OralDose: 9 mg daily + 32 mg daily | Infliximab + azathioprineRoute: IV + OralDose: 5 mg/kg + 2-2.5 mg/kg | CDAI (Remission: CDAI<150, absence of intestinal resection, absence of corticosteroid therapy) @ 14 wks | NAYes | Incidence 20 / 64 (32%) | Incidence 42 / 65 (65%) P: 0.0001 |
| D'Haens, 200848 | Budesonide + (6)-methylprednisoloneRoute: Oral + OralDose: 9 mg daily + 32 mg daily | Infliximab + azathioprineRoute: IV + OralDose: 5 mg/kg + 2-2.5 mg/kg | Endoscopic healing (Absence of ulcers) @ 104 wks | NANR | Incidence 7 / 23 (30%) | Incidence 19 / 26 (73%) P: 0.0028 |
| D'Haens, 200848 | Budesonide + (6)-methylprednisoloneRoute: Oral + OralDose: 9 mg daily + 32 mg daily | Infliximab + azathioprineRoute: IV + OralDose: 5 mg/kg + 2-2.5 mg/kg | Endoscopic healing (SES-CD) @ 104 wks | NANR | F: Mean, 3.1 (SD, 2.9) P: <0.001 | F: Mean, 0.7 (SD, 1.5) P: <0.001 |
| Sandborn, 200739 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 16 wks | NAYes | Incidence 86 / 331 (26%) | Incidence 66 / 328 (20%) |
| Sandborn, 200739 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 43 / 331 (13%) | Incidence 26 / 328 (8%) |
| Sandborn, 200739 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 26 wks | NAYes | Incidence 95 / 327 (29%) | Incidence 59 / 326 (18%) |
| Sandborn, 200739 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ response (≥16-pt increase)) @ 26 wks | NAYes | Incidence 140 / 331 (42%) | Incidence 108 / 328 (33%) P: 0.01 |
| Sandborn, 200739 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ) @ 26 wks | NAYes | F-B: Mean, 26.4 (SD, 35)G1-G2: -5.9 | F-B: Mean, 20.5 (SD, 33)G1-G2: -5.9 P: 0.03 |
| Sandborn, 200739 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | Perianal disease (Complete fistula closure) @ 26 wks | NAYes | Incidence 14 / 46 (30%) | Incidence 19 / 61 (31%) |
| Targan, 200732 | NatalizumabRoute: IVDose: 300 mg every 4 wks | PlaceboRoute: IVDose: NR every 4 wks | CDAI (Remission: CDAI < 150) @ 12 wks | NA NA | Incidence 97 / 259 (38%) | Incidence 63 / 250 (25%) P: 0.001 |
| Targan, 200732 | NatalizumabRoute: IVDose: 300 mg every 4 wks | PlaceboRoute: IVDose: NR every 4 wks | CDAI (Remission: CDAI < 150) @ 8 wks | NA NA | Incidence 68 / 259 (26%) | Incidence 40 / 250 (16%) P: 0.002 |
| Targan, 200732 | NatalizumabRoute: IVDose: 300 mg every 4 wks | PlaceboRoute: IVDose: NR every 4 wks | HR QoL (IBDQ) @ 12 wks | NA NA | B: Mean, 123.6 (SD, 31)F-B: Mean, 26.7 (SD, 32) P: <0.001 | B: Mean, 122.5 (SD, 28)F-B: Mean, 15.2 (SD, 29)G1-G2: -11.5 |
| Sandborn, 200738 | AdalimumabRoute: SC | PlaceboRoute: SC |  (Complete fistula closure) @ 4 wks | NA NA | Incidence 1 / 20 (5%) | Incidence 2 / 25 (8%) |
| Sandborn, 200738 | AdalimumabRoute: SC | PlaceboRoute: SC | CDAI (Remission: CDAI < 150) @ 4 wks | NAYes | Incidence 34 / 159 (21%) | Incidence 12 / 166 (7%) |
| Sandborn, 200738 | AdalimumabRoute: SC | PlaceboRoute: SC | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 10 / 159 (6%) | Incidence 6 / 166 (4%) |
| Sandborn, 200738 | AdalimumabRoute: SC | PlaceboRoute: SC | HR QoL (IBDQ) @ 4 wks | NA NA | F: Mean, 150 P: <0.001 | F: Mean, 139 P: <0.001 |
| Sands, 200735 | Natalizumab + infliximabRoute: IV + IVDose: 300 mg every 4 wks + 5 mg/kg every 8 wks | Placebo + infliximabRoute: IV + IVDose: NA every 4 wks + 5 mg/kg every 8 wks | CDAI (Remission: CDAI < 150) | NAYes | Incidence 24 / 52 (46%) | Incidence 11 / 27 (41%) |
| Sands, 200735 | Natalizumab + infliximabRoute: IV + IVDose: 300 mg every 4 wks + 5 mg/kg every 8 wks | Placebo + infliximabRoute: IV + IVDose: NA every 4 wks + 5 mg/kg every 8 wks | HR QoL (IBDQ) @ 6 wks | NAYes | F-B: 12.3G1-G2: -3.2 | F-B: 9.1G1-G2: -3.2 |
| Sands, 200735 | Natalizumab + infliximabRoute: IV + IVDose: 300 mg every 4 wks + 5 mg/kg every 8 wks | Placebo + infliximabRoute: IV + IVDose: NA every 4 wks + 5 mg/kg every 8 wks | HR QoL (IBDQ) @ 10 wks | NAYes | F-B: Mean, 18.7G1-G2: -1.4 | F-B: Mean, 17.3G1-G2: -1.4 |
| Lemann, 200646 | Infliximab + azathioprine or 6-MPRoute: IVDose: 5 mg/kg + stable | Placebo + azathioprine or 6-MPRoute: IV + OralDose: NA + stable  | Endoscopic healing (Absence of ulcers) @ 24 wks | NAYes | Incidence 3 / 11 (27%) | Incidence 3 / 9 (33%) P: 0.77 |
| Lemann, 200646 | Infliximab + azathioprine or 6-MPRoute: IVDose: 5 mg/kg + stable | Placebo + azathioprine or 6-MPRoute: IV + OralDose: NA + stable  | Endoscopic healing (CDEIS) @ 24 wks | NANR | F-B: Median, -6.9 (IQR, -9.5 to -4.1)G1-G2: 5.7 | F-B: Median, -1.2 (IQR, -4.4 to 1.5)G1-G2: 5.7 P: 0.05 |
| Lemann, 200646 | Infliximab + azathioprine or 6-MPRoute: IVDose: 5 mg/kg + stable | Placebo + azathioprine or 6-MPRoute: IV + OralDose: NA + stable  | Steroid free (steroid-free remission (CDAI < 150)) @ 12 wks | NAYes | Incidence 41 / 55 (75%)OR: 4.9 (2.2 to 11)  | Incidence 21 / 56 (38%) |
| Lemann, 200646 | Infliximab + azathioprine or 6-MPRoute: IVDose: 5 mg/kg + stable | Placebo + azathioprine or 6-MPRoute: IV + OralDose: NA + stable  | Steroid free (steroid-free remission (CDAI < 150)) @ 24 wks | NAYes | Incidence 31 / 54 (57%)OR: 3.3 (1.5 to 7.4)P: 0.003  | Incidence 15 / 52 (29%) P: 0.003 |
| Lemann, 200646 | Infliximab + azathioprine or 6-MPRoute: IVDose: 5 mg/kg + stable | Placebo + azathioprine or 6-MPRoute: IV + OralDose: NA + stable  | Steroid free (steroid-free remission (CDAI < 150)) @ 52 wks | NAYes | Incidence 22 / 55 (40%)OR: 2.4 (1 to 5.7)P: 0.04  | Incidence 11 / 51 (22%) P: 0.04 |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 40 mg then 20 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | CDAI (Remission: CDAI < 150) @ 1 wk | NAYes | Incidence 12 / 74 (16%) | Incidence 5 / 74 (7%) |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 40 mg then 20 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | CDAI (Remission: CDAI < 150) @ 4 wks | NAYes | Incidence 13 / 74 (18%) | Incidence 9 / 74 (12%) |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 40 mg then 20 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | HR QoL (IBDQ) @ 1 wk | NAYes | B: Mean, 129F: Mean, 14314 | B: Mean, 131F: Mean, 14110 |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 40 mg then 20 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | HR QoL (IBDQ) @ 4 wks | NAYes | B: Mean, 129F: Mean, 147 P: NS18 | B: Mean, 131F: Mean, 147 P: NS16 |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 40 mg then 20 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | Perianal disease (50% fistula closure) @ 4 wks | NAYes | Incidence 3 / 4 (75%) | Incidence 2 / 6 (33%) |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 40 mg then 20 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | Perianal disease (Complete fistula closure) @ 4 wks | NAYes | Incidence 3 / 4 (75%) | Incidence 1 / 6 (17%) |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 80 mg then 40 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | CDAI (Remission: CDAI < 150) @ 1 wk | NAYes | Incidence 10 / 75 (13%) | Incidence 5 / 74 (7%) P: NS |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 80 mg then 40 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | CDAI (Remission: CDAI < 150) @ 4 wks | NAYes | Incidence 18 / 75 (24%) | Incidence 9 / 74 (12%) P: NS |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 80 mg then 40 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | HR QoL (IBDQ) @ 1 wk | NAYes | B: Mean, 128F: Mean, 146F-B: Mean: 18 | B: Mean, 131F: Mean, 141F-B: Mean: 10 |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 80 mg then 40 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | HR QoL (IBDQ) @ 4 wks | NAYes | B: Mean, 128F: Mean, 157 P: <0.0529 | B: Mean, 131F: Mean, 147 P: <0.0516 |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 80 mg then 40 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | Perianal disease (50% fistula closure) @ 4 wks | NAYes | Incidence 2 / 10 (20%) | Incidence 2 / 6 (33%) |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 80 mg then 40 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | Perianal disease (Complete fistula closure) @ 4 wks | NAYes | Incidence 0 / 10 (0%) | Incidence 1 / 6 (17%) |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 160 mg then 80 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | CDAI (Remission: CDAI < 150) @ 1 wk | NAYes | Incidence 12 / 76 (16%) | Incidence 5 / 74 (7%) P: NS |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 160 mg then 80 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | CDAI (Remission: CDAI < 150) @ 4 wks | NAYes | Incidence 27 / 76 (36%) | Incidence 9 / 74 (12%) P: 0.001 |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 160 mg then 80 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | HR QoL (IBDQ) @ 1 wk | NAYes | B: Mean, 127F: Mean, 14619 | B: Mean, 131F: Mean, 14110 |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 160 mg then 80 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | HR QoL (IBDQ) @ 4 wks | NAYes | B: Mean, 127F: Mean, 157 P: <0.0530 | B: Mean, 131F: Mean, 147 P: <0.0516 |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 160 mg then 80 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | Perianal disease (50% fistula closure) @ 4 wks | NAYes | Incidence 1 / 12 (8%) | Incidence 2 / 6 (33%) |
| Hanauer, 200637 | AdalimumabRoute: SCDose: 160 mg then 80 mg every 2 wks | PlaceboRoute: SCDose: NA every 2 wks | Perianal disease (Complete fistula closure) @ 4 wks | NAYes | Incidence 0 / 12 (0%) | Incidence 1 / 6 (17%) |
| Schroder, 200647 | Methotrexate + infliximabRoute: IV + IVDose: 20 mg weekly + 5 mg/kg every 2 wks | InfliximabRoute: IVDose: 5 mg/kg every 2 wks | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 7 / 11 (64%) | Incidence 2 / 8 (25%) P: 0.16 |
| Schroder, 200647 | Methotrexate + infliximabRoute: IV + IVDose: 20 mg weekly + 5 mg/kg every 2 wks | InfliximabRoute: IVDose: 5 mg/kg every 2 wks | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 9 / 11 (82%) | Incidence 4 / 8 (50%) P: 0.32 |
| Schroder, 200647 | Methotrexate + infliximabRoute: IV + IVDose: 20 mg weekly + 5 mg/kg every 2 wks | InfliximabRoute: IVDose: 5 mg/kg every 2 wks | CDAI (Remission: CDAI < 150) @ 48 wks | NAYes | Incidence 5 / 11 (45%) | Incidence 2 / 8 (25%) P: 0.63 |
| Schroder, 200647 | Methotrexate + infliximabRoute: IV + IVDose: 20 mg weekly + 5 mg/kg every 2 wks | InfliximabRoute: IVDose: 5 mg/kg every 2 wks | HR QoL (IBDQ) @ 2 wks | NAYes | B: Mean, 113 (SD, 23)F: Mean, 160F-B: Mean: 47 | B: Mean, 106 (SD, 17)F: Mean, 135F-B: Mean: 29 |
| Schroder, 200647 | Methotrexate + infliximabRoute: IV + IVDose: 20 mg weekly + 5 mg/kg every 2 wks | InfliximabRoute: IVDose: 5 mg/kg every 2 wks | HR QoL (IBDQ) @ 12 wks | NAYes | B: Mean, 113 (SD, 23)F: Mean, 172F-B: Mean: 59 | B: Mean, 106 (SD, 17)F: Mean, 140F-B: Mean: 34 |
| Schroder, 200647 | Methotrexate + infliximabRoute: IV + IVDose: 20 mg weekly + 5 mg/kg every 2 wks | InfliximabRoute: IVDose: 5 mg/kg every 2 wks | HR QoL (IBDQ) @ 48 wks | NAYes | B: Mean, 113 (SD, 23)F: Mean, 165F-B: Mean: 52 | B: Mean, 106 (SD, 17)F: Mean, 130F-B: Mean: 24 |
| Schroder, 200647 | Methotrexate + infliximabRoute: IV + IVDose: 20 mg weekly + 5 mg/kg every 2 wks | InfliximabRoute: IVDose: 5 mg/kg every 2 wks | Steroid free (Discontinued corticosteroids) @ 48 wks | NAYes | Incidence 7 / 7 (100%) | Incidence 2 / 6 (33%) P: 0.02 |
| Sandborn, 200533 | NatalizumabRoute: IVDose: 300 mg every 4 wks | PlaceboRoute: IVDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 101 / 724 (14%) | Incidence 18 / 181 (10%) |
| Sandborn, 200533 | NatalizumabRoute: IVDose: 300 mg every 4 wks | PlaceboRoute: IVDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 10 wks | NAYes | Incidence 268 / 724 (37%) | Incidence 54 / 181 (30%) P: 0.12 |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 100 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 13 / 74 (18%) | Incidence 6 / 73 (8%) |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 100 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 20 / 74 (27%) | Incidence 17 / 73 (23.3%) |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 100 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ) @ 2 wks | NAYes | B: Mean, 132.2F-B: Mean, 16.6G1-G2: -6 | B: Mean, 122.9F-B: Mean, 10.6G1-G2: -6 P: <0.05 |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 100 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ) @ 12 wks | NAYes | B: Mean, 132.2F-B: 22G1-G2: -6 | B: Mean, 122.9F-B: 16G1-G2: -6 P: NS |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 100 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ > 170) @ 2 wks | NAYes | Incidence 24 / 73 (32.9%) | Incidence 13 / 73 (17.8%) |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 100 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ > 170) @ 12 wks | NAYes | Incidence 28 / 73 (38.4%) | Incidence 17 / 73 (23.3%) |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 200 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 7 / 72 (10%) | Incidence 6 / 73 (8%) P: NS |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 200 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 14 / 72 (19.4%) | Incidence 17 / 73 (23.3%) P: NS |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 200 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ) @ 2 wks | NAYes | B: Mean, 122.9F-B: Mean, 21.8G1-G2: -11.2 | B: Mean, 122.9F-B: Mean, 10.6G1-G2: -11.2 P: <0.05 |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 200 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ) @ 12 wks | NAYes | B: Mean, 122.9F-B: 20G1-G2: -4 | B: Mean, 122.9F-B: 16G1-G2: -4 P: NS |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 200 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ > 170) @ 2 wks | NAYes | Incidence 14 / 72 (19.4%) | Incidence 13 / 73 (17.8%) P: NS |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 200 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ > 170) @ 12 wks | NAYes | Incidence 17 / 72 (23.6%) | Incidence 17 / 73 (23.3%) P: NS |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 13 / 72 (18%) | Incidence 6 / 73 (8%) P: NS |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 19 / 72 (26.4%) | Incidence 17 / 73 (23.3%) P: NS |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ > 170) @ 2 wks | NAYes | Incidence 20 / 72 (27.8%) | Incidence 13 / 73 (17.8%) P: NS |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ > 170) @ 12 wks | NAYes | Incidence 28 / 72 (38.9%) | Incidence 17 / 73 (23.3%) P: <0.05 |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ) @ 2 wks | NA NA | B: Mean, 126.5 (SD, 25)F-B: Mean, 22.8G1-G2: -12.2 | B: Mean, 122.9 (SD, 27)F-B: Mean, 10.6G1-G2: -12.2 |
| Schreiber, 200540 | Certolizumab pegolRoute: SCDose: 400 mg every 4 wks | PlaceboRoute: SCDose: NA every 4 wks | HR QoL (IBDQ) @ 12 wks | NANR | B: Mean, 126.5 (SD, 25)F: Mean, 156.4 (SD, 37)F-B: Mean, 29.9 | B: Mean, 122.9 (SD, 27)F: Mean, 140.5 (SD, 36)F-B: Mean, 17.6G1-G2: -14 P: <0.05 |
| Winter, 200441 | Certolizumab pegolRoute: IVDose: 5 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 9 / 25 (35%) | Incidence 4 / 25 (16%) |
| Winter, 200441 | Certolizumab pegolRoute: IVDose: 5 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 8 / 25 (32%) | Incidence 8 / 25 (32%) |
| Winter, 200441 | Certolizumab pegolRoute: IVDose: 10 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 8 / 17 (47.1%) | Incidence 4 / 25 (16%) P: 0.041 |
| Winter, 200441 | Certolizumab pegolRoute: IVDose: 10 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 4 / 17 (23.5%) | Incidence 8 / 25 (32%) |
| Winter, 200441 | Certolizumab pegolRoute: IVDose: 20 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 5 / 23 (20%) | Incidence 4 / 25 (16%) |
| Winter, 200441 | Certolizumab pegolRoute: IVDose: 20 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 3 / 23 (12%) | Incidence 8 / 25 (32%) |
| Ardizzone, 200358 | MethotrexateRoute: IV for first 3 mos then oralDose: 25 mg weekly | AzathioprineRoute: OralDose: 2 mg/kg daily | Steroid free (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 12 / 27 (44%) | Incidence 9 / 27 (33%) |
| Ardizzone, 200358 | MethotrexateRoute: IV for first 3 mos then oralDose: 25 mg weekly | AzathioprineRoute: OralDose: 2 mg/kg daily | Perianal disease (Complete fistula closure) @ 24 wks | NANR | Incidence 4 / 6 (67%) | Incidence 1 / 4 (25%) |
| Tremaine, 200265 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA daily | CDAI (Remission: CDAI < 150) @ 2 wks | NANo | Incidence 31 / 78 (40%) | Incidence 5 / 40 (13%) |
| Tremaine, 200265 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA daily | CDAI (Remission: CDAI < 150) @ 8 wks | NANo | Incidence 41 / 78 (53%) | Incidence 13 / 40 (33%) P: >0.05 |
| Tremaine, 200265 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA daily | CDAI (Remission: treatment benefit (CDAI <150 or 100 pt drop)) @ 2 wks | NANo | Incidence 45 / 78 (58%) | Incidence 11 / 40 (27%) |
| Tremaine, 200265 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA daily | CDAI (Remission: treatment benefit (CDAI <150 or 100 pt drop)) @ 8 wks | NANo | Incidence 50 / 78 (64%) | Incidence 18 / 40 (44%) |
| Tremaine, 200265 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA daily | HR QoL (IBDQ) @ 8 wks | NANo | F-B: numerical improvements in total score', 34.1 (SD, 35.2) | F-B: numerical improvements in total score', 29.3 (SD, 35.7)G1-G2: -4.8 |
| Tremaine, 200265 | BudesonideRoute: OralDose: 9 mg daily | PlaceboRoute: OralDose: NA daily | CDAI (Remission: CDAI < 150) @ 2 wks | NANo | Incidence 24 / 79 (31%) | Incidence 5 / 40 (13%) |
| Tremaine, 200265 | BudesonideRoute: OralDose: 9 mg daily | PlaceboRoute: OralDose: NA daily | CDAI (Remission: CDAI < 150) @ 8 wks | NANo | Incidence 37 / 79 (48%) | Incidence 13 / 40 (33%) |
| Tremaine, 200265 | BudesonideRoute: OralDose: 9 mg daily | PlaceboRoute: OralDose: NA daily | CDAI (Remission: treatment benefit (CDAI <150 or 100 pt drop)) @ 2 wks | NANo | Incidence 38 / 79 (48%) | Incidence11 / 40 (27%) |
| Tremaine, 200265 | BudesonideRoute: OralDose: 9 mg daily | PlaceboRoute: OralDose: NA daily | CDAI (Remission: treatment benefit (CDAI <150 or 100 pt drop)) @ 8 wks | NANo | Incidence 52 / 79 (66%) | Incidence18 / 40 (44%) |
| Tremaine, 200265 | BudesonideRoute: OralDose: 9 mg daily | PlaceboRoute: OralDose: NA daily | HR QoL (IBDQ) @ 8 wks | NANo | F-B: numerical improvements in total score', 36.3 (SD, 32.5) | F-B: numerical improvements in total score', 29.3 (SD, 35.7)G1-G2: -7 |
| Gordon, 200134 | NatalizumabRoute: IVDose: 3 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 7 / 18 (39%) | Incidence 1 / 12 (8%) P: 0.1 |
| Gordon, 200134 | NatalizumabRoute: IVDose: 3 mg/kg | PlaceboRoute: IVDose: NA | HR QoL (IBDQ) @ 4 wks | NANR | F-B: Mean, 19 P: 0.004 |  |
| Mate-Jimenez, 200052 | MethotrexateRoute: OralDose: 15 mg weekly | 6-MPRoute: OralDose: 1.5 mg/kg daily | Steroid free (Remission: CDAI < 150 and normal serum orosmucoid concentration) @ 30 wks | NANR | Incidence 12 / 15 (80%) | Incidence 15 / 16 (93.7%) |
| Mate-Jimenez, 200052 | MethotrexateRoute: OralDose: 15 mg weekly | 6-MPRoute: OralDose: 1.5 mg/kg daily | Steroid free (Remission: CDAI < 150 and normal serum orosmucoid concentration) @ 106 wks | NANo | Incidence 8 / 15 (53%) | Incidence 8 / 16 (50%) |
| Mate-Jimenez, 200052 | ASARoute: OralDose: 3 g daily | 6-MPRoute: OralDose: 1.5 mg/kg daily | Steroid free (Remission: CDAI < 150 and normal serum orosmucoid concentration)@ 30 wks | NANR | Incidence 1 / 7 (14%) | Incidence 15 / 16 (93.7%) |
| Mate-Jimenez, 200052 | ASARoute: OralDose: 3 g daily | 6-MPRoute: OralDose: 1.5 mg/kg daily | Steroid free (Remission: CDAI < 150 and normal serum orosmucoid concentration) @ 106 wks | NANo | Incidence 0 / 7 (0%) | Incidence 8 / 16 (50%) |
| Mate-Jimenez, 200052 | ASARoute: OralDose: 3 g daily | MethotrexateRoute: OralDose: 15 mg weekly | Steroid free (Remission: CDAI < 150 and normal serum orosmucoid concentration)@ 30 wks | NANR | Incidence 1 / 7 (14%) | Incidence 12 / 15 (80%) |
| Mate-Jimenez, 200052 | ASARoute: OralDose: 3 g daily | MethotrexateRoute: OralDose: 15 mg weekly | Steroid free (Remission: CDAI < 150 and normal serum orosmucoid concentration)@ 106 wks | NANo | Incidence 0 / 7 (0%) | Incidence 8 / 15 (53%) |
| Sandborn, 199959 | Azathioprine + azathioprineRoute: IV + OralDose: 40 mg/kg + 2 mg/kg daily | Placebo + azathioprineRoute: IV + OralDose: NA + 2 mg/kg daily | CDAI (Remission: CDAI < 150) @ 8 wks | NAYes | Incidence 13 / 51 (25%) | Incidence 11 / 45 (24%) P: 0.906 |
| Sandborn, 199959 | Azathioprine + azathioprineRoute: IV + OralDose: 40 mg/kg + 2 mg/kg daily | Placebo + azathioprineRoute: IV + OralDose: NA + 2 mg/kg daily | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 11 / 51 (22%) | Incidence 10 / 45 (22%) P: 0.939 |
| Sandborn, 199959 | Azathioprine + azathioprineRoute: IV + OralDose: 40 mg/kg + 2 mg/kg daily | Placebo + azathioprineRoute: IV + OralDose: NA + 2 mg/kg daily | CDAI (Remission: CDAI < 150) @ 16 wks | NAYes | Incidence 16 / 51 (31%) | Incidence 12 / 45 (27%) P: 0.615 |
| Prantera, 199971 | (6)-MethylprednisoloneRoute: OralDose: 40 mg | Mesalamine (Asacol)Route: Oral (tablets)Dose: 4 g daily | CDAI (Remission: CDAI < 150) @ 3 wks | NAYes | Incidence 19 / 31 (61%) | Incidence 16 / 35 (46%) |
| Prantera, 199971 | (6)-MethylprednisoloneRoute: OralDose: 40 mg | Mesalamine (Asacol)Route: Oral (tablets)Dose: 4 g daily | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 19 / 31 (61%) | Incidence 21 / 35 (60%) |
| Prantera, 199971 | (6)-MethylprednisoloneRoute: OralDose: 40 mg | Mesalamine (Asacol)Route: Oral (granules)Dose: 4 g daily | CDAI (Remission: CDAI < 150) @ 3 wks | NAYes | Incidence 19 / 31 (61%) | Incidence 17 / 28 (61%) |
| Prantera, 199971 | (6)-MethylprednisoloneRoute: OralDose: 40 mg | Mesalamine (Asacol)Route: Oral (granules)Dose: 4 g daily | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 19 / 31 (61%) | Incidence 22 / 28 (79%) |
| Bar-Meir, 199867 | Prednisone + placeboRoute: Oral + OralDose: 40 mg daily + NA every 8 hrs | Budesonide + placeboRoute: OralDose: 3 mg every 8 hrs + NA daily | HR QoL (SF-36, physical score) @ 8 wks | NAYes | B: Mean, 40.8 (SD, 16.3)F: Mean, 62.3 (SD, 22)F-B: 21.5G1-G2: 8 | B: Mean, 44.8 (SD, 16.2)F: Mean, 58.3 (SD, 20.9)F-B: 13.5 |
| Bar-Meir, 199867 | Prednisone + placeboRoute: Oral + OralDose: 40 mg daily + NA every 8 hrs | Budesonide + placeboRoute: OralDose: 3 mg every 8 hrs + NA daily | HR QoL (SF-36, mental score) @ 8 wks | NAYes | B: Mean, 42.2 (SD, 19.7)F: Mean, 60.9 (SD, 23.1) F-B: 18.7G1-G2: 8 | B: Mean, 46.5 (SD, 18.9)F: Mean, 56.9 (SD, 20.7) F-B: 10.4 |
| Bar-Meir, 199867 | Prednisone + placeboRoute: Oral + OralDose: 40 mg daily + NA every 8 hrs | Budesonide + placeboRoute: OralDose: 3 mg every 8 hrs + NA daily | HR QoL (IBDQ) @ 8 wks | NAYes | B: Mean, 130.1 (SD, 32)F: Mean, 164.4 (SD, 36) F-B: Mean, 34.3G1-G2: 8 | B: Mean, 135.9 (SD, 28)F: Mean, 162 (SD, 34) F-B: Mean, 26.1 |
| Thomsen, 199870 | Mesalamine (Pentasa)Route: OralDose: 2 g every 12 hrs | Budesonide + placeboRoute: Oral + OralDose: 9 mg daily + NA daily | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 30 / 83 (36%) | Incidence 39 / 89 (44%) |
| Thomsen, 199870 | Mesalamine (Pentasa)Route: OralDose: 2 g every 12 hrs | Budesonide + placeboRoute: Oral + OralDose: 9 mg daily + NA daily | CDAI (Remission: CDAI < 150) @ 16 wks | NAYes | Incidence 18 / 50 (36%) | Incidence 48 / 77 (62%) |
| Thomsen, 199870 | Mesalamine (Pentasa)Route: OralDose: 2 g every 12 hrs | Budesonide + placeboRoute: Oral + OralDose: 9 mg daily + NA daily | HR QoL (PGWB) @ 2 wks | NA NA | B: 83F: Mean, 95 P: <0.05 | B: 81F: Mean, 98 P: <0.05 |
| Thomsen, 199870 | Mesalamine (Pentasa)Route: OralDose: 2 g every 12 hrs | Budesonide + placeboRoute: Oral + OralDose: 9 mg daily + NA daily | HR QoL (Psychological General Well-Being index) @ 16 wks | NAYes | B: Mean, 83F: Mean, 95 P: 0.01F-B: Mean, 9 (SD, 21) P: 0.0025G1-G2: 11.4 | B: Mean, 81F: Mean, 101 P: 0.01F-B: Mean, 20.4 (SD, 24) |
| Thomsen, 199870 | Mesalamine (Pentasa)Route: OralDose: 2 g every 12 hrs | Budesonide + placeboRoute: Oral + OralDose: 9 mg daily + NA daily | HR QoL (physician's global evaluation score) @ 2 wks | NAYes | B: Mean, 2.2F: Mean, 1.7 P: <0.01 F-B: Mean, -0.5 | B: Mean, 2.2F: Mean, 1.3 P: <0.01 F-B: Mean, -0.9 |
| Thomsen, 199870 | Mesalamine (Pentasa)Route: OralDose: 2 g every 12 hrs | Budesonide + placeboRoute: Oral + OralDose: 9 mg daily + NA daily | HR QoL (physician's global assessment) @ 16 wks | NAYes | B: Mean, 2.2F: 1.8 P: <0.001 | B: Mean, 2.2F: 1.2 P: <0.001 |
| Oren, 199757 | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HBI (Remission: HBI<3 and not on steroids) @ 4 wks | NAYes | Incidence 0 / 32 (0%) | Incidence 1 / 26 (5%) |
| Oren, 199757 | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HBI (Remission: HBI<3 and not on steroids) @ 16 wks | NAYes | Incidence 10 / 32 (30%) | Incidence 7 / 26 (28%) |
| Oren, 199757 | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HBI (Remission: HBI < 3 and not on steroids) @ 38 wks | NAYes | Incidence 13 / 32 (41%) | Incidence 12 / 26 (46%) |
| Oren, 199757 | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HBI (Relapse rate: HBI increased by 3+ points and/or require restarting steroid treatment at >300 mg/mo) @ 38 wks | NANo | Incidence 5 / 13 (38%) | Incidence 4 / 12 (33%) |
| Oren, 199757 | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HR QoL (Treatment Goal Score for Wellbeing) @ 4 wks | NANR | B: Mean, 0F: Mean, 0.8F-B: 0.8 | B: Mean, 0F: Mean, 0.8F-B: 0.8 |
| Oren, 199757 | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HR QoL (Treatment Goal Score for Wellbeing) @ 16 wks | NANR | B: Mean, 0F: Mean, 1.2F-B: 1.2 | B: Mean, 0F: Mean, 1F-B: 1 |
| Oren, 199757 | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HR QoL (Treatment Goal Score for Wellbeing) @ 38 wks | NANR | B: Mean, 0F: Mean, 1.3F-B: 1.3 | B: Mean, 0F: Mean, 1F-B: 1 |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HBI (Remission: HBI<3 and not on steroids) @ 4 wks | NAYes | Incidence 2 / 26 (8%) | Incidence 1 / 26 (5%) |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HBI (Remission: HBI<3 and not on steroids) @ 16 wks | NAYes | Incidence 8 / 26 (30%) | Incidence 7 / 26 (28%) |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HBI (Remission: HBI < 3 and not on steroids) @ 38 wks | NAYes | Incidence 10 / 26 (38%) | Incidence 12 / 26 (46%) |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HBI (Relapse rate: HBI increased by 3+ points and/or require restarting steroid treatment at >300mg/mo) @ 38 wks | NANo | Incidence 1 / 10 (10%) | Incidence 4 / 12 (33%) |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HR QoL (Treatment Goal Score for Wellbeing) @ 4 wks | NANR | B: Mean, 0F: Mean, 1.2F-B: 1.2 | B: Mean, 0F: Mean, 0.8F-B: 0.8 |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HR QoL (Treatment Goal Score for Wellbeing) @ 16 wks | NANR | B: Mean, 0F: Mean, 1.2F-B: 1.2 | B: Mean, 0F: Mean, 1F-B: 1 |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | Placebo + placeboRoute: Oral + OralDose: NA every 24 hrs + NA weekly | HR QoL (Treatment Goal Score for Wellbeing) @ 38 wks | NANR | B: Mean, 0F: Mean, 2.7F-B: 2.7 | B: Mean, 0F: Mean, 1F-B: 1 |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | HBI (Remission: HBI<3 and not on steroids) @ 4 wks | NAYes | Incidence 2 / 26 (8%) | Incidence 0 / 32 (0%) |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | HBI (Remission: HBI<3 and not on steroids) @ 16 wks | NAYes | Incidence 8 / 26 (30%) | Incidence 10 / 32 (30%) |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | HBI (Remission: HBI < 3 and not on steroids) @ 38 wks | NAYes | Incidence 10 / 26 (38%) | Incidence 13 / 32 (41%) |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | HBI (Relapse rate: HBI increased by 3+ points and/or require restarting steroid treatment at >300mg/mo) @ 38 wks | NANo | Incidence 1 / 10 (10%) | Incidence 5 / 13 (38%) |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | HR QoL (Treatment Goal Score for Wellbeing) @ 4 wks | NANR | B: Mean, 0F: Mean, 1.2 F-B: Mean, 1.2 | B: Mean, 0F: Mean, 0.8 F-B: Mean, 0.8 |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | HR QoL (Treatment Goal Score for Wellbeing) @ 16 wks | NANR | B: Mean, 0F: Mean, 1.2 F-B: Mean, 1.2 | B: Mean, 0F: Mean, 1.2 F-B: Mean, 1.2 |
| Oren, 199757 | Methotrexate + placeboRoute: Oral + OralDose: 12.5 mg weekly + NA every 24 hrs | 6-MP + placeboRoute: Oral + OralDose: 50 mg every 24 hrs + NA weekly | HR QoL (Treatment Goal Score for Wellbeing) @ 38 wks | NANR | B: Mean, 0F: Mean, 2.7 F-B: Mean, 2.7 | B: Mean, 0F: Mean, 1.3 F-B: Mean, 1.3 |
| Targan, 199743 | InfliximabRoute: IVDose: 5 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 2 wks | NANo | Incidence 10 / 26 (37%) | Incidence 1 / 24 (4%) |
| Targan, 199743 | InfliximabRoute: IVDose: 5 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 12 wks | NANo | Incidence 8 / 27 (30%) | Incidence 2 / 25 (8%) |
| Targan, 199743 | InfliximabRoute: IVDose: 5 mg/kg | PlaceboRoute: IVDose: NA | Endoscopic healing (CDEIS) @ 4 wks | NAYes | B: Mean, 15 (SE, 7)F: Mean, 6 (SE, 5) P: <0.01 F-B: Mean, -8.7 | B: Mean, 8 (SE, 6)F: Mean, 7 (SE, 5) P: <0.01 F-B: Mean, -0.9 |
| Targan, 199743 | InfliximabRoute: IVDose: 5 mg/kg | PlaceboRoute: IVDose: NA | HR QoL (IBDQ) @ 4 wks | NANo | B: Mean, 122 (SD, 29)F: Mean, 168 (SD, 36) F-B: Mean, 46 | B: Mean, 128 (SD, 29)F: Mean, 133 (SD, 28) F-B: Mean, 5 P: <0.001 |
| Targan, 199743 | InfliximabRoute: IVDose: 10 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 2 wks | NANo | Incidence 5 / 23 (20%) | Incidence 1 / 24 (4%) P: NS |
| Targan, 199743 | InfliximabRoute: IVDose: 10 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 12 wks | NANo | Incidence 5 / 28 (18%) | Incidence 2 / 25 (8%) |
| Targan, 199743 | InfliximabRoute: IVDose: 10 mg/kg | PlaceboRoute: IVDose: NA | Endoscopic healing (CDEIS) @ 4 wks | NAYes | B: Mean, 11 (SE, 8)F: Mean, 4 (SE, 5) P: <0.01 F-B: Mean, -6.3 | B: Mean, 8 (SE, 6)F: Mean, 7 (SE, 5) P: <0.01 F-B: Mean, -0.9 |
| Targan, 199743 | InfliximabRoute: IVDose: 10 mg/kg | PlaceboRoute: IVDose: NA | HR QoL (IBDQ) @ 4 wks | NANo | B: Mean, 116 (SD, 23)F: Mean, 146 (SD, 41) F-B: Mean, 30 | B: Mean, 128 (SD, 29)F: Mean, 133 (SD, 28) F-B: Mean, 5 P: 0.02 |
| Targan, 199743 | InfliximabRoute: IVDose: 20 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 2 wks | NANo | Incidence 6 / 28 (20%) | Incidence 1 / 24 (4%) P: NS |
| Targan, 199743 | InfliximabRoute: IVDose: 20 mg/kg | PlaceboRoute: IVDose: NA | CDAI (Remission: CDAI < 150) @ 12 wks | NANo | Incidence 7 / 28 (25%) | Incidence 2 / 25 (8%) |
| Targan, 199743 | InfliximabRoute: IVDose: 20 mg/kg | PlaceboRoute: IVDose: NA | Endoscopic healing (CDEIS) @ 4 wks | NAYes | B: Mean, 13.3 (SE, 6.9)F: Mean, 5.2 (SE, 2.8) P: <0.01 F-B: Mean, -8.1 | B: Mean, 8.4 (SE, 6.3)F: Mean, 7.5 (SE, 5.4) P: <0.01 F-B: Mean, -0.9 |
| Targan, 199743 | InfliximabRoute: IVDose: 20 mg/kg | PlaceboRoute: IVDose: NA | HR QoL (IBDQ) @ 4 wks | NANo | B: Mean, 118 (SD, 28)F: Mean, 149 (SD, 35) F-B: Mean, 31 | B: Mean, 128 (SD, 29)F: Mean, 133 (SD, 28) F-B: Mean, 5 P: 0.03 |
| Campieri, 199768 | Budesonide + placeboRoute: Oral + OralDose: 4.5 mg every 12 hrs + NA every 24 hrs | Prednisolone + placeboRoute: Oral + OralDose: 40 mg daily + NA every 12 hrs | CDAI (Remission: CDAI < 150) @ 2 wks | NANR | Incidence 16 / 61 (27%) | Incidence 21 / 58 (37%) |
| Campieri, 199768 | Budesonide + placeboRoute: Oral + OralDose: 4.5 mg every 12 hrs + NA every 24 hrs | Prednisolone + placeboRoute: Oral + OralDose: 40 mg daily + NA every 12 hrs | CDAI (Remission: CDAI < 150) @ 12 wks | NANR | Incidence 31 / 61 (51%) | Incidence 31 / 58 (53%) |
| Campieri, 199768 | Budesonide + placeboRoute: Oral + OralDose: 9 mg daily + NA every 24 hrs | Prednisolone + placeboRoute: Oral + OralDose: 40 mg daily + NA every 12 hrs | CDAI (Remission: CDAI < 150) @ 2 wks | NANR | Incidence 28 / 58 (48%) | Incidence 21 / 58 (37%) |
| Campieri, 199768 | Budesonide + placeboRoute: Oral + OralDose: 9 mg daily + NA every 24 hrs | Prednisolone + placeboRoute: Oral + OralDose: 40 mg daily + NA every 12 hrs | CDAI (Remission: CDAI < 150) @ 12 wks | NANR | Incidence 34 / 58 (58%) | Incidence 31 / 58 (53%) |
| Candy, 199553 | Placebo + prednisoloneRoute: Oral + OralDose: NA + 1 mg/kg daily | Azathioprine + prednisoloneRoute: Oral + OralDose: 2.5 mg/kg daily + 1 mg/kg daily | CDAI (Remission: CDAI < 150) @ 12 wks | NAYes | Incidence 19 / 30 (63%) | Incidence 24 / 33 (73%) P: 0.6 |
| Candy, 199553 | Placebo + prednisoloneRoute: Oral + OralDose: NA + 1 mg/kg daily | Azathioprine + prednisoloneRoute: Oral + OralDose: 2.5 mg/kg daily + 1 mg/kg daily | CDAI (Remission: CDAI < 150) @ 60 wks | NA NA | Incidence 2 / 30 (7%) | Incidence 14 / 33 (42%) P: 0.001 |
| Candy, 199553 | Placebo + prednisoloneRoute: Oral + OralDose: NA + 1 mg/kg daily | Azathioprine + prednisoloneRoute: Oral + OralDose: 2.5 mg/kg daily + 1 mg/kg daily | CDAI (Remission: CDAI<175) @ 64 wks | NAYes | Incidence 14 / 33 (42%)RR: 6.36 (1.6 to 25.7) | Incidence 2 / 30 (7%) P: 0.001 |
| Gross, 199572 | (6)-MethylprednisoloneRoute: OralDose: 48 mg/d every 24 hrs | ASA (Salofalk)Route: OralDose: 1.5 g every 8 hrs | CDAI (Remission: CDAI<150 and 60-pt drop) @ 2 wks | NAYes | Incidence 1 / 16 (8%) | Incidence 1 / 15 (8%) |
| Gross, 199572 | (6)-MethylprednisoloneRoute: OralDose: 48 mg/d every 24 hrs | ASA (Salofalk)Route: OralDose: 1.5 g every 8 hrs | CDAI (Remission: CDAI<150 and 60-pt drop) @ 8 wks | NAYes | Incidence 9 / 16 (56.3%) | Incidence 6 / 15 (40%) P: 0.5867 |
| Feagan, 199563 | Methotrexate + prednisoneRoute: IM + OralDose: 25 mg weekly | Placebo + prednisoneRoute: IM + OralDose: NA weekly + daily | CDAI (Remission: discontinuation of prednisone therapy and CDAI ≤ 150 pts) @ 16 wks | NAYes | Incidence 37 / 94 (39%)RR: 1.95 (1.09 to 3.48)P: 0.025 vs. main | Incidence 9 / 47 (19%) P: 0.025 |
| Feagan, 199563 | Methotrexate + prednisoneRoute: IM + OralDose: 25 mg weekly | Placebo + prednisoneRoute: IM + OralDose: NA weekly + daily | HR QoL (IBDQ) @ 2 wks | NAYes | B: Mean, 162F: Mean, 167 F-B: Mean, 5 | B: Mean, 159F: Mean, 161 F-B: Mean, 2 |
| Feagan, 199563 | Methotrexate + prednisoneRoute: IM + OralDose: 25 mg weekly | Placebo + prednisoneRoute: IM + OralDose: NA weekly + daily | HR QoL (IBDQ) @ 16 wks | NAYes | B: Mean, 162 (SE, 17)F: Mean, 169 (SE, 4) P: <.002 F-B: Mean, 7 | B: Mean, 159 (SE, 5)F: Mean, 151 (SE, 6) P: <.002 F-B: Mean, -8 |
| Tremaine, 199477 | Mesalamine (Asacol)Route: OralDose: 800 mg every 6 hrs | PlaceboRoute: OralDose: NA every 6 hrs | CDAI (Remission: CDAI<150 and 70 pt drop) @ 16 wks | NAYes | Incidence 9 / 20 (45%) | Incidence 4 / 18 (22%) |
| Rutgeerts, 199469 | Prednisolone + placeboRoute: Oral + OralDose: 40 mg every 24 hrs + NA daily | Budesonide + placeboRoute: Oral + OralDose: 9 mg every 24 hrs | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 48 / 88 (56%) | Incidence 39 / 88 (45%) P: 0.22 |
| Rutgeerts, 199469 | Prednisolone + placeboRoute: Oral + OralDose: 40 mg every 24 hrs + NA daily | Budesonide + placeboRoute: Oral + OralDose: 9 mg every 24 hrs | CDAI (Remission: CDAI < 150) @ 10 wks | NAYes | Incidence 58 / 88 (66%) | Incidence 47 / 88 (53%) P: 0.12 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 1.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 7 / 67 (10%) | Incidence 7 / 66 (11%) |
| Greenberg, 199466 | BudesonideRoute: OralDose: 1.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | CDAI (Remission: CDAI < 150) @ 8 wks | NAYes | Incidence 22 / 67 (33%) | Incidence 13 / 66 (20%) P: 0.13 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 1.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | CDAI (Relapse rate: CDAI >150 and 60-pt increase) | NA NA | Event rate 124 events | Event rate 39 events |
| Greenberg, 199466 | BudesonideRoute: OralDose: 1.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | CDAI (Relapse rate: CDAI >150 and 60-pt increase) @ 52 wks | NA NA | Incidence 23 / 33 (70%) | Incidence 24 / 36 (67%) |
| Greenberg, 199466 | BudesonideRoute: OralDose: 1.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | HR QoL (IBDQ) @ 2 wks | NAYes | B: Mean, 131F: Mean, 142 F-B: Mean, 11 | B: Mean, 130F: Mean, 141 F-B: Mean, 11 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 1.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | HR QoL (IBDQ) @ 8 wks | NAYes | B: Mean, 131F: Mean, 140 F-B: Mean, 9 | B: Mean, 130F: Mean, 141 F-B: Mean, 11 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 1.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | HR QoL (IBDQ) @ 12 wks | NA NA | B: Mean, 185 (SD, 21)F: Mean, 170 (SD, 39) F-B: Mean, -15 | B: Mean, 181 (SD, 19)F: Mean, 154 (SD, 35) F-B: Mean, -27 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 1.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | HR QoL (IBDQ) @ 52 wks | NA NA | B: Mean, 185 (SD, 21)F: Mean, 156 (SD, 39) F-B: Mean, -29 | B: Mean, 181 (SD, 19)F: Mean, 150 (SD, 38) F-B: Mean, -31 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | CDAI (Relapse rate: CDAI >150 and 60-pt increase) | NA NA | Event rate 178 days | Event rate 39 events / ds |
| Greenberg, 199466 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | CDAI (Relapse rate: CDAI >150 and 60-pt increase) @ 52 wks | NA NA | Incidence 22 / 36 (61%) | Incidence 24 / 36 (67%) |
| Greenberg, 199466 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 21 / 61 (34%) | Incidence 7 / 66 (11%) |
| Greenberg, 199466 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | CDAI (Remission: CDAI < 150) @ 8 wks | NAYes | Incidence 31 / 61 (51%) | Incidence 13 / 66 (20%) P: <0.001 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | HR QoL (IBDQ) @ 2 wks | NAYes | B: Mean, 125F: Mean, 157 P: 0.0002 F-B: Mean, 32 | B: Mean, 130F: Mean, 141 P: 0.0002 F-B: Mean, 11 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | HR QoL (IBDQ) @ 8 wks | NAYes | B: Mean, 125F: Mean, 166 P: <0.001 F-B: Mean, 41 | B: Mean, 130F: Mean, 141 P: <0.001 F-B: Mean, 11 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | HR QoL (IBDQ) @ 12 wks | NA NA | B: Mean, 184 (SD, 24)F: Mean, 172 (SD, 35) F-B: Mean, -12 | B: Mean, 181 (SD, 19)F: Mean, 154 (SD, 35) F-B: Mean, -27 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 4.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | HR QoL (IBDQ) @ 52 wks | NA NA | B: Mean, 184 (SD, 24)F: Mean, 161 (SD, 36) F-B: Mean, -23 | B: Mean, 181 (SD, 19)F: Mean, 150 (SD, 38) F-B: Mean, -31 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 7.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | CDAI (Remission: CDAI < 150) @ 2 wks | NAYes | Incidence 17 / 64 (27%) | Incidence 7 / 66 (11%) |
| Greenberg, 199466 | BudesonideRoute: OralDose: 7.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | CDAI (Remission: CDAI < 150) @ 8 wks | NAYes | Incidence 28 / 64 (43%) | Incidence 13 / 66 (20%) P: 0.009 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 7.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | HR QoL (IBDQ) @ 2 wks | NAYes | B: Mean, 130F: Mean, 155 P: 0.006 F-B: Mean, 25 | B: Mean, 130F: Mean, 141 P: 0.006 F-B: Mean, 11 |
| Greenberg, 199466 | BudesonideRoute: OralDose: 7.5 mg every 12 hrs | PlaceboRoute: OralDose: NA every 12 hrs | HR QoL (IBDQ) @ 8 wks | NAYes | B: Mean, 130F: Mean, 154 P: 0.012 F-B: Mean, 24 | B: Mean, 130F: Mean, 141 P: 0.012 F-B: Mean, 11 |
| Ewe, 199354 | Azathioprine + prednisoloneDose: 2.5 mg/kg daily + 60 mg daily | Placebo + prednisoloneDose: 60 mg daily | CDAI (Remission: CDAI < 150) | NANR | Incidence 16 / 21 (76%) | Incidence 8 / 21 (38%) P: 0.061 |
| Malchow, 198464 | SulfasalazineRoute: OralDose: 3 g every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: failure to fall to less than 150 points or rise to above 150) @ 104 wks | NANo | Incidence 25 / 42 (60%) | Incidence 32 / 42 (75%) P: ns |
| Malchow, 198464 | SulfasalazineRoute: OralDose: 3 g every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: rise of CDAI to over 150 during the study period) @ 104 wks | NANo | Incidence 45 / 75 (60%) |  P: NS |
| Malchow, 198464 | SulfasalazineRoute: OralDose: 3 g every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: CDAI not coming down to less than 150 even after 2 AP treatments) @ 104 wks | NANo | Incidence 56 / 75 (75%) |  P: <0.05 |
| Malchow, 198464 | SulfasalazineRoute: OralDose: 3 g every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: increase to more than 150 or in patients with active disease at randomization did not fall to less than 150 after 2 AP treatments) @ 104 wks | NANo | Incidence 49 / 75 (65%) |  P: <0.05 |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: IVDose: 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: failure to fall to less than 150 points or rise to above 150) @ 104 wks | NANo | Incidence 25 / 38 (65%) | Incidence 32 / 42 (75%) P: ns |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: increase to more than 150 or in patients with active disease at randomization did not fall to less than 150 after 2 AP treatments) @ 104 wks | NANo | Incidence 40 / 75 (53%) |  P: <0.001 |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: CDAI not coming down to less than 150 even after 2 AP treatments) @ 104 wks | NANo | Incidence 49 / 75 (65%) |  P: <0.001 |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: rise of CDAI to over 150 during the study period.) @ 104 wks | NANo | Incidence 38 / 75 (50%) |  P: NS |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: failure to fall to less than 150 points or rise to above 150) @ 104 wks | NANo | Incidence 23 / 38 (60%) | Incidence 32 / 42 (75%) P: <0.05 |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: CDAI not coming down to less than 150 even after 2 AP treatments) @ 104 wks | NANo | Incidence 48 / 74 (65%) |  P: <0.001 |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: rise of CDAI to over 150 during the study period.) @ 104 wks | NANo | Incidence 48 / 74 (65%) |  P: NS |
| Malchow, 198464 | SulfasalazineRoute: OralDose: 3 g every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: increase to more than 150 or in patients with active disease at randomization did not fall to less than 150 after 2 AP treatments) @ 104 wks | NANo | Incidence 49 / 75 (65%) | Incidence 51 / 68 (75%) |
| Malchow, 198464 | SulfasalazineRoute: OralDose: 3 g every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: CDAI not coming down to less than 150 even after 2 AP treatments) @ 104 wks | NANo | Incidence 56 / 75 (75%) | Incidence 61 / 68 (90%) |
| Malchow, 198464 | SulfasalazineRoute: OralDose: 3 g every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: rise of CDAI to over 150 during the study period.) @ 104 wks | NANo | Incidence 45 / 75 (60%) | Incidence 44 / 68 (65%) |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: increase to more than 150 or in patients with active disease at randomization did not fall to less than 150 after 2 AP treatments) @ 104 wks | NANo | Incidence 40 / 75 (53%) | Incidence 51 / 68 (75%) |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: CDAI not coming down to less than 150 even after 2 AP treatments) @ 104 wks | NANo | Incidence 49 / 75 (65%) | Incidence 61 / 68 (90%) |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: rise of CDAI to over 150 during the study period.) @ 104 wks | NANo | Incidence 38 / 75 (50%) | Incidence 44 / 68 (65%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: increase to more than 150 or in patients with active disease at randomization did not fall to less than 150 after 2 AP treatments) @ 104 wks | NANo | Incidence 23 / 38 (60%) | Incidence 51 / 68 (75%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: rise of CDAI to over 150 during the study period) @ 104 wks | NANo | Incidence 48 / 74 (65%) | Incidence 44 / 68 (65%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Relapse rate: CDAI not coming down to less than 150 even after 2 AP treatments) @ 104 wks | NANo | Incidence 48 / 74 (65%) | Incidence 61 / 68 (90%) |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: IVDose: 48 mg every 24 hrs | SulfasalazineRoute: OralDose: 3 g every 24 hrs | CDAI (Relapse rate: failure to fall to less than 150 points or rise to above 150) @ 104 wks | NANo | Incidence 25 / 38 (65%) | Incidence 25 / 42 (60%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | SulfasalazineRoute: OralDose: 3 g every 24 hrs | CDAI (Relapse rate: failure to fall to less than 150 points or rise to above 150) @ 104 wks | NANo | Incidence 23 / 38 (60%) | Incidence 25 / 42 (60%) |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | SulfasalazineRoute: OralDose: 3 g every 24 hrs | CDAI (Relapse rate: increase to more than 150 or in patients with active disease at randomization did not fall to less than 150 after 2 AP treatments) @ 104 wks | NANo | Incidence 40 / 75 (53%) | Incidence 49 / 75 (65%) |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | SulfasalazineRoute: OralDose: 3 g every 24 hrs | CDAI (Relapse rate: CDAI not coming down to less than 150 even after 2 AP treatments) @ 104 wks | NANo | Incidence 49 / 75 (65%) | Incidence 56 / 75 (75%) |
| Malchow, 198464 | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | SulfasalazineRoute: OralDose: 3 g every 24 hrs | CDAI (Relapse rate: rise of CDAI to over 150 during the study period.) @ 104 wks | NANo | Incidence 38 / 75 (50%) | Incidence 45 / 75 (60%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | SulfasalazineRoute: OralDose: 3 g every 24 hrs | CDAI (Relapse rate: increase to more than 150 or in patients with active disease at randomization did not fall to less than 150 after 2 AP treatments) @ 104 wks | NANo | Incidence 23 / 38 (60%) | Incidence 49 / 75 (65%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | SulfasalazineRoute: OralDose: 3 g every 24 hrs | CDAI (Relapse rate: CDAI not coming down to less than 150 even after 2 AP treatments) @ 104 wks | NANo | Incidence 48 / 74 (65%) | Incidence 56 / 75 (75%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | SulfasalazineRoute: OralDose: 3 g every 24 hrs | CDAI (Relapse rate: rise of CDAI to over 150 during the study period.) @ 104 wks | NANo | Incidence 48 / 74 (65%) | Incidence 45 / 75 (60%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | (6)-MethylprednisoloneRoute: IVDose: 48 mg every 24 hrs | CDAI (Relapse rate: failure to fall to less than 150 points or rise to above 150) @ 104 wks | NANo | Incidence 23 / 38 (60%) | Incidence 25 / 38 (65%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | CDAI (Relapse rate: increase to more than 150 or in patients with active disease at randomization did not fall to less than 150 after 2 AP treatments) @ 104 wks | NANo | Incidence 23 / 38 (60%) | Incidence 40 / 75 (53%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | CDAI (Relapse rate: rise of CDAI to over 150 during the study period.) @ 104 wks | NANo | Incidence 48 / 74 (65%) | Incidence 38 / 75 (50%) |
| Malchow, 198464 | Sulfasalazine + prednisoloneRoute: Oral + UnknownDose: 3 g every 24 hrs + 48 mg every 24 hrs | (6)-MethylprednisoloneRoute: UnknownDose: 48 mg every 24 hrs | CDAI (Relapse rate: CDAI not coming down to less than 150 even after 2 AP treatments) @ 104 wks | NANo | Incidence 48 / 74 (65%) | Incidence 49 / 75 (65%) |
| Present, 198060 | 6-MPRoute: UnknownDose: 1.5 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | Steroid free (stopping steroid use in patients) @ 104 wks | NANo | Incidence 24 / 44 (55%) | Incidence 14 / 39 (36%) |
| Singleton, 197975 | Sulfasalazine + prednisoneRoute: Oral + UnknownDose: 1g per 15kg body weight to 5g max daily + daily | Placebo + prednisoneRoute: Unknown + OralDose: NA + daily | CDAI (Remission: CDAI < 150) @ 8 wks | NANR | Incidence 25 / 43 (57%) | Incidence 35 / 46 (76%) |
| Summers, 197956 | SulfasalazineRoute: OralDose: 1g/15kgs daily | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 5 / 74 (7%) | Incidence 4 / 77 (5%) |
| Summers, 197956 | SulfasalazineRoute: OralDose: 1g/15kgs daily | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 11 / 74 (15%) | Incidence 17 / 77 (22%) |
| Summers, 197956 | SulfasalazineRoute: OralDose: 1g/15kgs daily | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 39 / 74 (53%) | Incidence 38 / 77 (50%) |
| Summers, 197956 | SulfasalazineRoute: OralDose: 1g/15kgs daily | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 33 / 74 (45%) | Incidence 23 / 77 (30%) P: 0.08 |
| Summers, 197956 | SulfasalazineRoute: OralDose: 1g/15kgs daily | PlaceboRoute: OralDose: NA | Perianal disease (Complete fistula closure) @ 104 wks | NANo | Incidence 2 / 9 (22%) | Incidence 1 / 9 (11%) |
| Summers, 197956 | PrednisoneRoute: OralDose: If CDAI<150 then dose of prednisone is 1/4mg/kg, if CDAI = 150-300 then prednisone was dosed at 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 11 / 85 (13%) | Incidence 4 / 77 (5%) |
| Summers, 197956 | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 25 / 85 (29%) | Incidence 17 / 77 (22%) |
| Summers, 197956 | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 66 / 85 (78%) | Incidence 38 / 77 (50%) |
| Summers, 197956 | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 51 / 85 (60%) | Incidence 23 / 77 (30%) P: <0.0001 |
| Summers, 197956 | PrednisoneRoute: OralDose: If CDAI<150 then dose of prednisone is 1/4mg/kg, if CDAI = 150-300 then prednisone was dosed at 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | Perianal disease (Complete fistula closure) @ 104 wks | NANo | Incidence 3 / 10 (30%) | Incidence 1 / 9 (11%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 13 / 59 (22%) | Incidence 17 / 77 (22%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 1 / 59 (2%) | Incidence 4 / 77 (5%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 25 / 59 (43%) | Incidence 23 / 77 (30%) P: 0.17 |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 32 / 59 (55%) | Incidence 38 / 77 (50%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | Perianal disease (Complete fistula closure) @ 104 wks | NANo | Incidence 1 / 8 (12%) | Incidence 1 / 9 (11%) |
| Summers, 197956 | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | SulfasalazineRoute: OralDose: 1g/15kgs every 24 hrs | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 25 / 85 (29%) | Incidence 11 / 74 (15%) |
| Summers, 197956 | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | SulfasalazineRoute: OralDose: 1g/15kgs every 24 hrs | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 11 / 85 (13%) | Incidence 5 / 74 (7%) |
| Summers, 197956 | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | SulfasalazineRoute: OralDose: 1g/15kgs every 24 hrs | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 66 / 85 (78%) | Incidence 39 / 74 (53%) |
| Summers, 197956 | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | SulfasalazineRoute: OralDose: 1g/15kgs every 24 hrs | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 51 / 85 (60%) | Incidence 33 / 74 (45%) |
| Summers, 197956 | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | SulfasalazineRoute: OralDose: 1g/15kgs every 24 hrs | Perianal disease (Complete fistula closure) @ 104 wks | NANo | Incidence 3 / 10 (30%) | Incidence 2 / 9 (22%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | SulfasalazineRoute: OralDose: 1g/15kgs every 24 hrs | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 1 / 59 (2%) | Incidence 5 / 74 (7%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | SulfasalazineRoute: OralDose: 1g/15kgs every 24 hrs | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 13 / 59 (22%) | Incidence 11 / 74 (15%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | SulfasalazineRoute: OralDose: 1g/15kgs every 24 hrs | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 25 / 59 (43%) | Incidence 33 / 74 (45%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | SulfasalazineRoute: OralDose: 1g/15kgs every 24 hrs | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 32 / 59 (55%) | Incidence 39 / 74 (53%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | SulfasalazineRoute: OralDose: 1g/15kgs every 24 hrs | Perianal disease (Complete fistula closure) @ 104 wks | NANo | Incidence 1 / 8 (12%) | Incidence 2 / 9 (22%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 13 / 59 (22%) | Incidence 25 / 85 (29%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | CDAI (Remission: CDAI < 150) @1 wk | NAYes | Incidence 1 / 59 (2%) | Incidence 11 / 85 (13%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 25 / 59 (43%) | Incidence 51 / 85 (60%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | CDAI (Remission: CDAI < 150) @ 17 wks | NANo | Incidence 32 / 59 (55%) | Incidence 66 / 85 (78%) |
| Summers, 197956 | AzathioprineRoute: OralDose: 2.5 mg/kg every 24 hrs | PrednisoneRoute: OralDose: If CDAI<150 then 1/4mg/kg, if CDAI = 150-300 then 1/2mg/kg, if CDAI >300 then 3/4mg/kg every 24 hrs | Perianal disease (Complete fistula closure) @ 104 wks | NANo | Incidence 1 / 8 (12%) | Incidence 3 / 10 (30%) |
| O'Donoghue, 1978100 | AzathioprineRoute: OralDose: 2 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | (Relapse rate: Cumulative probability of relapse after 6 mos relapse clinically defined) @ 24 wks | NANo | G1-G2: Mean, 0% | G1-G2: Mean, 25% P: <0.01 |
| O'Donoghue, 1978100 | AzathioprineRoute: OralDose: 2 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | (Relapse rate: Cumulative probability of relapse after 6 mos relapse clinically defined) @ 52 wks | NANo | G1-G2: Mean, 5% | G1-G2: Mean, 41% P: <0.01 |
| O'Donoghue, 1978100 | AzathioprineRoute: OralDose: 2 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | Unnamed disease activity score (Score change from baseline) @ 52 wks | NANo | F-B: Mean, 0.63 P: <0.05G1-G2: 1.8 | F-B: Mean, 2.46G1-G2: 1.8 |
| Klein, 197462 | AzathioprineRoute: OralDose: 3 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | Reduction of steroids (reduction in the average dose of prednisone) @ 16 wks | NANo | B: Mean, 13.3 (SD, 3.5)F: Mean, 6.3 (SD, 1.6) F-B: Mean, -7 | B: Mean, 19.8 (SD, 5.9)F: Mean, 7.8 (SD, 3) F-B: Mean, -12 |
| Klein, 197462 | AzathioprineRoute: OralDose: 3 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | Reduction of steroids (reduction in the dose of prednisone) @ 32 wks | NANo | B: Mean, 4.4F: Mean, 1.7 F-B: Mean, -2.7 | B: Mean, 5.2F: Mean, 5 F-B: Mean, -0.2 |
| Klein, 197462 | AzathioprineRoute: OralDose: 3 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | HR QoL (subjective feeling of improvement) @ 16 wks | NANo | Incidence 6 / 13 (46%) | Incidence 6 / 13 (46%) |
| Klein, 197462 | AzathioprineRoute: OralDose: 3 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | HR QoL (subjective feeling of no change) @ 16 wks | NANo | Incidence 5 / 13 (38%) | Incidence 5 / 13 (38%) |
| Rhodes, 197161 | AzathioprineRoute: OralDose: 4 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | HR QoL (Subjective feeling of being better after treatment) @ 8 wks | NANR | Incidence 0 / 8 (0%) | Incidence 0 / 7 (0%) |
| Rhodes, 197161 | AzathioprineRoute: OralDose: 4 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | HR QoL (subjective feeling of being worse after treatment) @ 8 wks | NANo | Incidence 2 / 8 (25%) | Incidence 1 / 7 (14%) |
| Rhodes, 197161 | AzathioprineRoute: OralDose: 4 mg/kg every 24 hrs | PlaceboRoute: OralDose: NA | HR QoL (Subjective feeling of 'No difference' after treatment) @ 8 wks | NANo | Incidence 6 / 8 (75%) | Incidence 6 / 7 (86%) |
| Singleton, 199379 | Mesalamine (Pentasa)Route: OralDose: 1 g daily | PlaceboRoute: OralDose: NA daily | CDAI (Remission: 50-point drop and a final CDAI < 151) @ 16 wks | NAYes | Incidence 18 / 80 (23%) | Incidence 14 / 80 (18%) |
| Singleton, 199379 | Mesalamine (Pentasa)Route: OralDose: 1 g daily | PlaceboRoute: OralDose: NA daily | HBI (Absolute HBI) @ 16 wks | NAYes | F-B: Mean, -0.4 (SE, 0.5) | F-B: Mean, -0.9 (SE, 0.5)G1-G2: -0.5 P: NS |
| Singleton, 199379 | Mesalamine (Pentasa)Route: OralDose: 2 g daily | PlaceboRoute: OralDose: NA daily | CDAI (Remission: 50-point drop and a final CDAI < 151) @ 16 wks | NAYes | Incidence 18 / 75 (24%) | Incidence 14 / 80 (18%) P: NS |
| Singleton, 199379 | Mesalamine (Pentasa)Route: OralDose: 2 g daily | PlaceboRoute: OralDose: NA daily | HBI (Absolute HBI) @ 16 wks | NAYes | F-B: Mean, -1.2 (SE, 0.5) | F-B: Mean, -0.9 (SE, 0.5)G1-G2: 0.3 P: NS |
| Singleton, 199379 | Mesalamine (Pentasa)Route: OralDose: 4 g daily | PlaceboRoute: OralDose: NA daily | CDAI (Remission: 50-point drop and a final CDAI < 151) @ 16 wks | NAYes | Incidence 32 / 75 (43%) | Incidence 14 / 80 (18%) P: 0.0017 |
| Singleton, 199379 | Mesalamine (Pentasa)Route: OralDose: 4 g daily | PlaceboRoute: OralDose: NA daily | HBI (Absolute HBI) @ 16 wks | NAYes | F-B: Mean, -2.8 (SE, 0.5) | F-B: Mean, -0.9 (SE, 0.5)G1-G2: 1.9 P: 0.0054 |
| Present, 199944 | InfliximabRoute: IVDose: 5 mg/kg | PlaceboRoute: IV | Perianal disease (Perianal disease activity index) @ 2 wks | NANo | B: Median, 8 (IQR, 7 to 10)F: Median, 6 (IQR, 3 to 7) P: 0.02 | B: Median, 9 (IQR, 7 to 10.5)F: Median, 8 (IQR, 6 to 10) P: 0.02 |
| Present, 199944 | InfliximabRoute: IVDose: 5 mg/kg | PlaceboRoute: IV | Perianal disease (Perianal Disease Activity Index) @ 18 wks | NANo | B: Median, 8 (IQR, 7 to 10)F: Median, 4 (IQR, 1 to 7) P: 0.05 | B: Median, 9 (IQR, 7 to 10.5)F: Median, 7 (IQR, 4 to 9) P: 0.05 |
| Present, 199944 | InfliximabRoute: IVDose: 5 mg/kg | PlaceboRoute: IV | Perianal disease (50% fistula closure) @ 18 wks | NAYes | Incidence 21 / 31 (68%) | Incidence 8 / 31 (26%) P: 0.002 |
| Present, 199944 | InfliximabRoute: IVDose: 5 mg/kg | PlaceboRoute: IV | Perianal disease (Complete fistula closure) @ 18 wks | NAYes | Incidence 17 / 31 (55%) | Incidence 4 / 31 (13%) P: 0.001 |
| Present, 199944 | InfliximabRoute: IVDose: 10 mg/kg | PlaceboRoute: IV | Perianal disease (Perianal disease activity index) @ 2 wks | NANo | B: Median, 10 (IQR, 8 to 12)F: Median, 6 (IQR, 4 to 8) P: 0.04 | B: Median, 9 (IQR, 7 to 10.5)F: Median, 8 (IQR, 6 to 10) P: 0.04 |
| Present, 199944 | InfliximabRoute: IVDose: 10 mg/kg | PlaceboRoute: IV | Perianal disease (Perianal Disease Activity Index) @ 18 wks | NANo | B: Median, 10 (IQR, 8 to 12)F: Median, 5 (IQR, 3 to 8) P: 0.14 | B: Median, 9 (IQR, 7 to 10.5)F: Median, 7 (IQR, 4 to 9) P: 0.14 |
| Present, 199944 | InfliximabRoute: IVDose: 10 mg/kg | PlaceboRoute: IV | Perianal disease (50% fistula closure) @ 18 wks | NAYes | Incidence 18 / 31 (58%) | Incidence 8 / 31 (26%) P: 0.02 |
| Present, 199944 | InfliximabRoute: IVDose: 10 mg/kg | PlaceboRoute: IV | Perianal disease (Complete fistula closure) @ 18 wks | NAYes | Incidence 12 / 32 (38%) | Incidence 4 / 31 (13%) P: 0.04 |
| Martin F, 199073 | PrednisoneRoute: OralDose: 40 mg every 24 hrs | ASA (Salofalk)Route: OralDose: 250 mg every 8 hrs | CDAI (Remission: CDAI < 150) @ 12 wks | NANo | Incidence 12 / 26 (46%) | Incidence 9 / 19 (47%) |
| Martin F, 199073 | PrednisoneRoute: OralDose: 40 mg every 24 hrs | ASA (Salofalk)Route: OralDose: 250 mg every 8 hrs | HR QoL (McMaster University quality of life index) @ 2 wks | NANo | G1-G2: Mean, 24 | G1-G2: Mean, 6 P: <0.005 |
| Martin F, 199073 | PrednisoneRoute: OralDose: 40 mg every 24 hrs | ASA (Salofalk)Route: OralDose: 250 mg every 8 hrs | HR QoL (McMaster University Quality of life index) @ 12 wks | NA NA | G1-G2: Mean, 38 | G1-G2: Mean, 36 P: NS |
| Martin F, 199073 | PrednisoneRoute: OralDose: 40 mg every 24 hrs | ASA (Salofalk)Route: OralDose: 250 mg every 8 hrs | HR QoL (McMaster University Quality of life - Bowel symptoms) @ 12 wks | NA NA | G1-G2: Mean, 38 | G1-G2: Mean, 38 P: NS |
| Martin F, 199073 | PrednisoneRoute: OralDose: 40 mg every 24 hrs | ASA (Salofalk)Route: OralDose: 250 mg every 8 hrs | HR QoL (McMaster University Quality of life index - Emotional function) @ 12 wks | NANo | G1-G2: Mean, 26 | G1-G2: Mean, 26 P: NS |
| Martin F, 199073 | PrednisoneRoute: OralDose: 40 mg every 24 hrs | ASA (Salofalk)Route: OralDose: 250 mg every 8 hrs | HR QoL (McMaster University Quality of life index - Social Function) @ 12 wks | NANo | G1-G2: Mean, 38 | G1-G2: Mean, 44 P: NS |
| Martin F, 199073 | PrednisoneRoute: OralDose: 40 mg every 24 hrs | ASA (Salofalk)Route: OralDose: 250 mg every 8 hrs | HR QoL (McMaster University Quality of life index - systemic symptoms) @ 2 wks | NANo | G1-G2: Mean, 42 | G1-G2: Mean, 2 P: <0.05 |
| Martin F, 199073 | PrednisoneRoute: OralDose: 40 mg every 24 hrs | ASA (Salofalk)Route: OralDose: 250 mg every 8 hrs | HR QoL (McMaster University Quality of life index - systemic symptoms) @ 12 wks | NANo | G1-G2: Mean, 50 | G1-G2: Mean, 48 P: NS |
| Schreiber, 201142 | Certolizumab pegolRoute: SCDose: 400 mg sc once | Placebo | Remission (CDAI < 150) @ 2 wks | NAYes | Incidence50 / 215 (23%) | Incidence33 / 209 (16%) P = 0.03 |
| Schreiber, 201142 | Certolizumab pegolRoute: SCDose: 400 mg sc once | Placebo | HR QoL (IBDQ Remission) @ 2 wsks | NAYes | 55 / 215 (26%) | 38 / 209 (18%) P = 0.059 |

Abbreviations: 95% CI = 95% Confidence Interval; 6-MP = 6-Mercaptopurine; @ = at; AP = Acute Phase; ASA = Aminosalicylates; CDAI = Crohn’s Disease Activity Index; CDEIS = Crohn’s Disease Endoscopic Index of Severity; g = gram; g/kgs = gram/kilograms; HBI = Harvey-Bradshaw Index; HR QoL= Health-related Quality of Life; hrs = hours; IBDQ = Inflammatory Bowel Disease Questionnaire; IFX= Infliximab; IM = intramuscular; IV= intravenous; IQR= inter-quartile range; kg = kilogram; Max. = maximum; mg = milligram; mg/d = milligram/day; mg/kg = milligram/kilogram; mg/mo = milligram/month; Min. = minimum; Mo/mos= month(s); NA = Not Applicable; NR= Not Reported; NS = not significant; OR: Odds Ratio; PGWB = Psychological General Well-Being; P = p-value; pt = point; SES-CD = Simplified Endoscopic Activity Score for Crohn’s Disease; SC = subcutaneous; SD = standard deviation; SE= standard error; Steroid free = steroid-free remission; TNF = tumor necrosis factor; TPMT= thiopurine methyltransferase; UTD = unable to determine; and wks = weeks.